title: Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation.
authors.affiliation: Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA. javier.munoz@bannerhealth.com
authors.forename: Javier
authors.initials: J
authors.lastname: Munoz
authors.forename: Ellen
authors.initials: E
authors.lastname: Schlette
authors.forename: Razelle
authors.initials: R
authors.lastname: Kurzrock
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001707:Biopsy, Needle; D001774:Blood Chemical Analysis; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000008:administration & dosage* / Q000009:adverse effects; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D009154:Mutation; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D012720:Severity of Illness Index; D013449:Sulfonamides / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf